Literature DB >> 16936131

Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations.

Samuel G Jacobson1, Artur V Cideciyan, Alexander Sumaroka, Tomas S Aleman, Sharon B Schwartz, Elizabeth A M Windsor, Alejandro J Roman, Edwin M Stone, Ian M MacDonald.   

Abstract

PURPOSE: To characterize in detail the disease expression in choroideremia (CHM), a blinding X-linked disease of the retina caused by loss-of-function mutations in Rab Escort Protein 1 (REP-1). CHM is readily diagnosed in the clinic and by molecular testing but has lacked an animal model to test hypotheses and therapeutics. The recent report of a mouse model for CHM prompts the need for reassessment of the human disease in anticipation of treatment initiatives.
METHODS: CHM hemizygotes with REP-1 mutations, spanning an age range of 7 decades, were studied with in vivo microscopy by optical coherence tomography.
RESULTS: The disease expression was complex. Earliest stages involved a thickening of the retina that was otherwise normally laminated. Loss of photoreceptors, either independent or associated with retinal pigment epithelium (RPE) depigmentation, was followed by disorganization and further thickening of the retina with interlaminar bridges. The dysmorphic retina then slowly thinned over decades. Laminopathy occurred first in more peripheral rod-rich regions and later in the cone-rich fovea.
CONCLUSIONS: The CHM disease sequence involves detectable retinal thickening, which may be due to Müller cell activation and hypertrophy from photoreceptor stress. Photoreceptor degeneration, RPE depigmentation, and retinal remodeling follow. The results represent in vivo evidence in humans for retinal remodeling and provide a marker for the earliest stage of this response to genetic retinal disease. For CHM and other candidate human retinopathies considered for therapy, there is now a framework for making informed decisions about timing, retinal location, and potential value of treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16936131     DOI: 10.1167/iovs.06-0424

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  65 in total

1.  Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept.

Authors:  Astra Dinculescu; Jackie Estreicher; Juan C Zenteno; Tomas S Aleman; Sharon B Schwartz; Wei Chieh Huang; Alejandro J Roman; Alexander Sumaroka; Qiuhong Li; Wen-Tao Deng; Seok-Hong Min; Vince A Chiodo; Andy Neeley; Xuan Liu; Xinhua Shu; Margarita Matias-Florentino; Beatriz Buentello-Volante; Sanford L Boye; Artur V Cideciyan; William W Hauswirth; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

2.  Transition zones between healthy and diseased retina in choroideremia (CHM) and Stargardt disease (STGD) as compared to retinitis pigmentosa (RP).

Authors:  Margot A Lazow; Donald C Hood; Rithambara Ramachandran; Tomas R Burke; Yi-Zhong Wang; Vivienne C Greenstein; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-20       Impact factor: 4.799

3.  Visual Function at the Atrophic Border in Choroideremia Assessed with Adaptive Optics Microperimetry.

Authors:  William S Tuten; Grace K Vergilio; Gloria J Young; Jean Bennett; Albert M Maguire; Tomas S Aleman; David H Brainard; Jessica I W Morgan
Journal:  Ophthalmol Retina       Date:  2019-05-08

4.  Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.

Authors:  Mohamed A Genead; Jason J McAnany; Gerald A Fishman
Journal:  Retina       Date:  2012-04       Impact factor: 4.256

5.  Correlation of outer nuclear layer thickness with cone density values in patients with retinitis pigmentosa and healthy subjects.

Authors:  Moreno Menghini; Brandon J Lujan; Shiri Zayit-Soudry; Reema Syed; Travis C Porco; Kristine Bayabo; Joseph Carroll; Austin Roorda; Jacque L Duncan
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-16       Impact factor: 4.799

6.  Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Ilaria Passerini; Simona Palchetti; Andrea Sodi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

Review 7.  A comprehensive review of retinal gene therapy.

Authors:  Shannon E Boye; Sanford L Boye; Alfred S Lewin; William W Hauswirth
Journal:  Mol Ther       Date:  2013-01-29       Impact factor: 11.454

8.  Inner and outer retinal changes in retinal degenerations associated with ABCA4 mutations.

Authors:  Wei Chieh Huang; Artur V Cideciyan; Alejandro J Roman; Alexander Sumaroka; Rebecca Sheplock; Sharon B Schwartz; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

9.  Retinal laminar architecture in human retinitis pigmentosa caused by Rhodopsin gene mutations.

Authors:  Tomas S Aleman; Artur V Cideciyan; Alexander Sumaroka; Elizabeth A M Windsor; Waldo Herrera; D Alan White; Shalesh Kaushal; Anjani Naidu; Alejandro J Roman; Sharon B Schwartz; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

10.  Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

Authors:  Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.